#11 - Back or Bolt⚡

Granted patents in GB and US on the core polymer technology - not pending, actually issued. The EU application is still in examination, so European protection isn't locked yet.

Real product performance data: the fibre reportedly demonstrates 100% post-stretch recovery and matches or beats spandex on tested parameters, while being non-toxic, biodegradable and recyclable - a genuine sustainability edge in a category (elastane) that's notoriously hard to recycle.

Independent institutional validation is unusually strong for this stage: five Innovate UK grants, the H&M Foundation Global Change Award (2023), and an Earthshot Prize nomination. These aren't marketing claims - they're competitive, externally judged awards.

A public Gymshark collaboration on seamless-knitting garments, plus an 80+ brand waitlist spanning apparel and automotive, and a signed LOI for 100kg+ of fibre - genuine commercial pull rather than just interest.

Two contracts already signed, which is more concrete commercial traction than most pre-revenue deep-tech raises show at this stage.

The team itself carries weight: a co-founder with 26 years in nanotech academia (Dr. Alexander Seifalian), a former NASA flight engineer, and founders with prior exits.

Named angel backers who are putting real reputational capital behind the round: the Chair of Starling Bank, the CEO of Apeiron Investments, a Founding Principal at Spin VC, and a former CMO of McLaren.

The fibre is designed as a drop-in replacement for existing textile manufacturing machinery, which lowers the adoption barrier for apparel brands considerably compared to a technology that requires new tooling.

Revenue is negligible: £3,967 in the most recent filed year (FY ended Nov 2025), following £494 and £1,556 in the two years before that. The company is being valued at £8m pre-money against essentially pre-revenue numbers.

Losses are growing, not narrowing: net loss went from £87.6k (FY2022) to £152.4k (FY2024) to £216.2k (FY2025) - the trend is the opposite of what you'd want to see heading into a raise this size.

The core IP is not owned by Nanoloom. It's exclusively licensed from NanoRegMed Ltd, a company majority-owned by co-founder Dr. Seifalian. This was directly and pointedly challenged in the Crowdcube discussion thread, and the company's response - that NanoRegMed is aligned because it's also a shareholder - doesn't fully address the structural risk: if the licence is ever terminated (which can happen automatically on payment default or an unapproved change of control), Nanoloom loses its right to the underlying technology entirely, and remaining inventory must be destroyed or returned.

NanoRegMed also holds a veto: it must give written consent to any future funding round that would dilute its stake below 24.99%, and can terminate the licence if there's a change of control above 50% that it hasn't approved. That's a real complication for future institutional rounds, restructurings, or an exit.

There's an existing historical debt of £82,975 to Nanoloom Limited (the licensor relationship) for past licence fees, plus new 2026 licence fees of £31,000 plus twelve monthly instalments - an ongoing cash obligation tied directly to the same related party that controls the IP.

The company is still transitioning from pilot to industrial-scale production. Nothing in the disclosure confirms that fibre quality holds up at the volumes the 80+ waitlist and signed LOI would require.

The commercial pipeline leans heavily on non-binding LOIs and a waitlist - real signals of interest, but not purchase orders. The company's own risk disclosure acknowledges this directly.

The company cannot sub-license the base polymer and must retain partial control over production via subcontracting - a supply chain complexity above and beyond the straightforward scaling problem.

EIS relief is confirmed at 30%, which does meaningfully soften the downside - but it doesn't change the underlying question of whether an £8m valuation is justified by four figures of annual revenue.